Astrocytes: Conductors of the Alzheimer disease neuroinflammatory symphony

Experimental Neurology

Volumn 239, Issue 1, 2013, Pages 133-138

  Medeiros, Rodrigo ^a   LaFerla, Frank M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; CELECOXIB; CYCLOOXYGENASE 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDOMETACIN; INTERLEUKIN 1BETA; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NIMESULIDE; TUMOR NECROSIS FACTOR ALPHA;

ALZHEIMER DISEASE; ASTROCYTE; AUTOPSY; CELL ACTIVATION; COGNITIVE DEFECT; CYTOKINE RELEASE; DISEASE COURSE; HUMAN; INFLAMMATION; MOLECULAR MECHANICS; NERVE CELL NECROSIS; NERVOUS SYSTEM INFLAMMATION; NEUROFIBRILLARY TANGLE; NONHUMAN; NOTE; PRIORITY JOURNAL; SENILE PLAQUE; SYNAPSE;

AMYLOID BETA-PEPTIDES; ANIMALS; ASTROCYTES; BRAIN CHEMISTRY; CYCLOOXYGENASE 2; FEMALE; INTERLEUKIN-1BETA; NF-KAPPA B; PEPTIDE FRAGMENTS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84868252916     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2012.10.007     Document Type: Note

References (100)

1. Aisen P.S., Thal L.J., Ferris S.H., Assaid C., Nessly M.L., Giuliani M.J., Lines C.R., Norman B.A., Potter W.Z. Rofecoxib in patients with mild cognitive impairment: further analyses of data from a randomized, double-blind, trial. Curr. Alzheimer Res. 2008, 5:73-82.
2. Akama K.T., Albanese C., Pestell R.G., Van Eldik L.J. Amyloid beta-peptide stimulates nitric oxide production in astrocytes through an NFkappaB-dependent mechanism. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:5795-5800.
3. Akiyama H., Barger S., Barnum S., Bradt B., Bauer J., Cole G.M., Cooper N.R., Eikelenboom P., Emmerling M., Fiebich B.L., Finch C.E., Frautschy S., Griffin W.S., Hampel H., Hull M., Landreth G., Lue L., Mrak R., Mackenzie I.R., McGeer P.L., O'Banion M.K., Pachter J., Pasinetti G., Plata-Salaman C., Rogers J., Rydel R., Shen Y., Streit W., Strohmeyer R., Tooyoma I., Van Muiswinkel F.L., Veerhuis R., Walker D., Webster S., Wegrzyniak B., Wenk G., Wyss-Coray T. Inflammation and Alzheimer's disease. Neurobiol. Aging 2000, 21:383-421.
4. Alexopoulou L., Kranidioti K., Xanthoulea S., Denis M., Kotanidou A., Douni E., Blackshear P.J., Kontoyiannis D.L., Kollias G. Transmembrane TNF protects mutant mice against intracellular bacterial infections, chronic inflammation and autoimmunity. Eur. J. Immunol. 2006, 36:2768-2780.
5. Allan S.M., Tyrrell P.J., Rothwell N.J. Interleukin-1 and neuronal injury. Nat. Rev. Immunol. 2005, 5:629-640.
6. Arnett H.A., Mason J., Marino M., Suzuki K., Matsushima G.K., Ting J.P. TNF alpha promotes proliferation of oligodendrocyte progenitors and remyelination. Nat. Neurosci. 2001, 4:1116-1122.
7. Ascolani A., Balestrieri E., Minutolo A., Mosti S., Spalletta G., Bramanti P., Mastino A., Caltagirone C., Macchi B. Dysregulated NF-kappaB pathway in peripheral mononuclear cells of Alzheimer's disease patients. Curr. Alzheimer Res. 2012, 9:128-137.
8. Attwell D., Buchan A.M., Charpak S., Lauritzen M., Macvicar B.A., Newman E.A. Glial and neuronal control of brain blood flow. Nature 2010, 468:232-243.
9. Blackburn D., Sargsyan S., Monk P.N., Shaw P.J. Astrocyte function and role in motor neuron disease: a future therapeutic target?. Glia 2009, 57:1251-1264.
10. Brambilla R., Bracchi-Ricard V., Hu W.H., Frydel B., Bramwell A., Karmally S., Green E.J., Bethea J.R. Inhibition of astroglial nuclear factor kappaB reduces inflammation and improves functional recovery after spinal cord injury. J. Exp. Med. 2005, 202:145-156.
11. Brambilla R., Hurtado A., Persaud T., Esham K., Pearse D.D., Oudega M., Bethea J.R. Transgenic inhibition of astroglial NF-kappa B leads to increased axonal sparing and sprouting following spinal cord injury. J. Neurochem. 2009, 110:765-778.
12. Brambilla R., Persaud T., Hu X., Karmally S., Shestopalov V.I., Dvoriantchikova G., Ivanov D., Nathanson L., Barnum S.R., Bethea J.R. Transgenic inhibition of astroglial NF-kappa B improves functional outcome in experimental autoimmune encephalomyelitis by suppressing chronic central nervous system inflammation. J. Immunol. 2009, 182:2628-2640.
13. Brissoni B., Agostini L., Kropf M., Martinon F., Swoboda V., Lippens S., Everett H., Aebi N., Janssens S., Meylan E., Felberbaum-Corti M., Hirling H., Gruenberg J., Tschopp J., Burns K. Intracellular trafficking of interleukin-1 receptor I requires Tollip. Curr. Biol. 2006, 16:2265-2270.
14. Burns K., Clatworthy J., Martin L., Martinon F., Plumpton C., Maschera B., Lewis A., Ray K., Tschopp J., Volpe F. Tollip, a new component of the IL-1RI pathway, links IRAK to the IL-1 receptor. Nat. Cell Biol. 2000, 2:346-351.
15. Cakala M., Malik A.R., Strosznajder J.B. Inhibitor of cyclooxygenase-2 protects against amyloid beta peptide-evoked memory impairment in mice. Pharmacol. Rep. 2007, 59:164-172.
16. Canault M., Peiretti F., Mueller C., Kopp F., Morange P., Rihs S., Portugal H., Juhan-Vague I., Nalbone G. Exclusive expression of transmembrane TNF-alpha in mice reduces the inflammatory response in early lipid lesions of aortic sinus. Atherosclerosis 2004, 172:211-218.
17. Carrero I., Gonzalo M.R., Martin B., Sanz-Anquela J.M., Arevalo-Serrano J., Gonzalo-Ruiz A. Oligomers of beta-amyloid protein (Abeta1-42) induce the activation of cyclooxygenase-2 in astrocytes via an interaction with interleukin-1beta, tumour necrosis factor-alpha, and a nuclear factor kappa-B mechanism in the rat brain. Exp. Neurol. 2012, 236:215-227.
18. Combrinck M., Williams J., De Berardinis M.A., Warden D., Puopolo M., Smith A.D., Minghetti L. Levels of CSF prostaglandin E2, cognitive decline, and survival in Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 2006, 77:85-88.
19. Didierlaurent A., Brissoni B., Velin D., Aebi N., Tardivel A., Kaslin E., Sirard J.C., Angelov G., Tschopp J., Burns K. Tollip regulates proinflammatory responses to interleukin-1 and lipopolysaccharide. Mol. Cell. Biol. 2006, 26:735-742.
20. Dinarello C.A. Immunological and inflammatory functions of the interleukin-1 family. Annu. Rev. Immunol. 2009, 27:519-550.
21. Dvoriantchikova G., Barakat D., Brambilla R., Agudelo C., Hernandez E., Bethea J.R., Shestopalov V.I., Ivanov D. Inactivation of astroglial NF-kappa B promotes survival of retinal neurons following ischemic injury. Eur. J. Neurosci. 2009, 30:175-185.
22. Farina C., Aloisi F., Meinl E. Astrocytes are active players in cerebral innate immunity. Trends Immunol. 2007, 28:138-145.
23. Feldmann M., Maini R.N. Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. Nat. Med. 2003, 9:1245-1250.
24. Fillit H., Ding W.H., Buee L., Kalman J., Altstiel L., Lawlor B., Wolf-Klein G. Elevated circulating tumor necrosis factor levels in Alzheimer's disease. Neurosci. Lett. 1991, 129:318-320.
25. Font-Nieves M., Sans-Fons M.G., Gorina R., Bonfill-Teixidor E., Salas-Perdomo A., Marquez-Kisinousky L., Santalucia T., Planas A.M. Induction of COX-2 enzyme and down-regulation of COX-1 expression by lipopolysaccharide (LPS) control prostaglandin E2 production in astrocytes. J. Biol. Chem. 2012, 287:6454-6468.
26. Forloni G., Demicheli F., Giorgi S., Bendotti C., Angeretti N. Expression of amyloid precursor protein mRNAs in endothelial, neuronal and glial cells: modulation by interleukin-1. Brain Res. Mol. Brain Res. 1992, 16:128-134.
27. Fromont A., De Seze J., Fleury M.C., Maillefert J.F., Moreau T. Inflammatory demyelinating events following treatment with anti-tumor necrosis factor. Cytokine 2009, 45:55-57.
28. Fu E.S., Zhang Y.P., Sagen J., Yang Z.Q., Bethea J.R. Transgenic glial nuclear factor-kappa B inhibition decreases formalin pain in mice. Neuroreport 2007, 18:713-717.
29. Grell M., Douni E., Wajant H., Lohden M., Clauss M., Maxeiner B., Georgopoulos S., Lesslauer W., Kollias G., Pfizenmaier K., Scheurich P. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell 1995, 83:793-802.
30. Halassa M.M., Haydon P.G. Integrated brain circuits: astrocytic networks modulate neuronal activity and behavior. Annu. Rev. Physiol. 2010, 72:335-355.
31. Harris J., Hartman M., Roche C., Zeng S.G., O'Shea A., Sharp F.A., Lambe E.M., Creagh E.M., Golenbock D.T., Tschopp J., Kornfeld H., Fitzgerald K.A., Lavelle E.C. Autophagy controls IL-1beta secretion by targeting pro-IL-1beta for degradation. J. Biol. Chem. 2011, 286:9587-9597.
32. He P., Zhong Z., Lindholm K., Berning L., Lee W., Lemere C., Staufenbiel M., Li R., Shen Y. Deletion of tumor necrosis factor death receptor inhibits amyloid beta generation and prevents learning and memory deficits in Alzheimer's mice. J. Cell Biol. 2007, 178:829-841.
33. Heneka M.T., Sastre M., Dumitrescu-Ozimek L., Hanke A., Dewachter I., Kuiperi C., O'Banion K., Klockgether T., Van Leuven F., Landreth G.E. Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice. Brain 2005, 128:1442-1453.
34. Henneberger C., Papouin T., Oliet S.H., Rusakov D.A. Long-term potentiation depends on release of D-serine from astrocytes. Nature 2010, 463:232-236.
35. Hinz B., Brune K. Cyclooxygenase-2-10 years later. J. Pharmacol. Exp. Ther. 2002, 300:367-375.
36. Hirst W.D., Young K.A., Newton R., Allport V.C., Marriott D.R., Wilkin G.P. Expression of COX-2 by normal and reactive astrocytes in the adult rat central nervous system. Mol. Cell. Neurosci. 1999, 13:57-68.
37. Ho L., Purohit D., Haroutunian V., Luterman J.D., Willis F., Naslund J., Buxbaum J.D., Mohs R.C., Aisen P.S., Pasinetti G.M. Neuronal cyclooxygenase 2 expression in the hippocampal formation as a function of the clinical progression of Alzheimer disease. Arch. Neurol. 2001, 58:487-492.
38. Holtmann M.H., Neurath M.F. Differential TNF-signaling in chronic inflammatory disorders. Curr. Mol. Med. 2004, 4:439-444.
39. Hoozemans J.J., Rozemuller A.J., Janssen I., De Groot C.J., Veerhuis R., Eikelenboom P. Cyclooxygenase expression in microglia and neurons in Alzheimer's disease and control brain. Acta Neuropathol. 2001, 101:2-8.
40. Janelsins M.C., Mastrangelo M.A., Oddo S., LaFerla F.M., Federoff H.J., Bowers W.J. Early correlation of microglial activation with enhanced tumor necrosis factor-alpha and monocyte chemoattractant protein-1 expression specifically within the entorhinal cortex of triple transgenic Alzheimer's disease mice. J. Neuroinflammation 2005, 2:23.
41. Janelsins M.C., Mastrangelo M.A., Park K.M., Sudol K.L., Narrow W.C., Oddo S., LaFerla F.M., Callahan L.M., Federoff H.J., Bowers W.J. Chronic neuron-specific tumor necrosis factor-alpha expression enhances the local inflammatory environment ultimately leading to neuronal death in 3xTg-AD mice. Am. J. Pathol. 2008, 173:1768-1782.
42. Jantzen P.T., Connor K.E., DiCarlo G., Wenk G.L., Wallace J.L., Rojiani A.M., Coppola D., Morgan D., Gordon M.N. Microglial activation and beta -amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice. J. Neurosci. 2002, 22:2246-2254.
43. Kaltschmidt B., Uherek M., Volk B., Baeuerle P.A., Kaltschmidt C. Transcription factor NF-kappaB is activated in primary neurons by amyloid beta peptides and in neurons surrounding early plaques from patients with Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:2642-2647.
44. Kim J.I., Jin J.K., Choi E.K., Spinner D., Rubenstein R., Carp R.I., Kim Y.S. Increased expression and localization of cyclooxygenase-2 in astrocytes of scrapie-infected mice. J. Neuroimmunol. 2007, 187:74-82.
45. Kitazawa M., Cheng D., Tsukamoto M.R., Koike M.A., Wes P.D., Vasilevko V., Cribbs D.H., LaFerla F.M. Blocking IL-1 signaling rescues cognition, attenuates tau pathology, and restores neuronal beta-catenin pathway function in an Alzheimer's disease model. J. Immunol. 2011, 187:6539-6549.
46. Koenigsknecht-Talboo J., Landreth G.E. Microglial phagocytosis induced by fibrillar beta-amyloid and IgGs are differentially regulated by proinflammatory cytokines. J. Neurosci. 2005, 25:8240-8249.
47. Kotilinek L.A., Westerman M.A., Wang Q., Panizzon K., Lim G.P., Simonyi A., Lesne S., Falinska A., Younkin L.H., Younkin S.G., Rowan M., Cleary J., Wallis R.A., Sun G.Y., Cole G., Frautschy S., Anwyl R., Ashe K.H. Cyclooxygenase-2 inhibition improves amyloid-beta-mediated suppression of memory and synaptic plasticity. Brain 2008, 131:651-664.
48. Kukar T., Murphy M.P., Eriksen J.L., Sagi S.A., Weggen S., Smith T.E., Ladd T., Khan M.A., Kache R., Beard J., Dodson M., Merit S., Ozols V.V., Anastasiadis P.Z., Das P., Fauq A., Koo E.H., Golde T.E. Diverse compounds mimic Alzheimer disease-causing mutations by augmenting Abeta42 production. Nat. Med. 2005, 11:545-550.
49. Lee J., Kim H.R., Quinley C., Kim J., Gonzalez-Navajas J., Xavier R., Raz E. Autophagy suppresses interleukin-1beta (IL-1beta) signaling by activation of p62 degradation via lysosomal and proteasomal pathways. J. Biol. Chem. 2012, 287:4033-4040.
50. Lemere C.A. A beneficial role for IL-1 beta in Alzheimer disease?. J. Clin. Invest. 2007, 117:1483-1485.
51. Li Y., Liu L., Barger S.W., Griffin W.S. Interleukin-1 mediates pathological effects of microglia on tau phosphorylation and on synaptophysin synthesis in cortical neurons through a p38-MAPK pathway. J. Neurosci. 2003, 23:1605-1611.
52. Li R., Yang L., Lindholm K., Konishi Y., Yue X., Hampel H., Zhang D., Shen Y. Tumor necrosis factor death receptor signaling cascade is required for amyloid-beta protein-induced neuron death. J. Neurosci. 2004, 24:1760-1771.
53. Maragakis N.J., Rothstein J.D. Mechanisms of disease: astrocytes in neurodegenerative disease. Nat. Clin. Pract. Neurol. 2006, 2:679-689.
54. Marnett L.J., Rowlinson S.W., Goodwin D.C., Kalgutkar A.S., Lanzo C.A. Arachidonic acid oxygenation by COX-1 and COX-2. Mechanisms of catalysis and inhibition. J. Biol. Chem. 1999, 274:22903-22906.
55. Maslinska D., Wozniak R., Kaliszek A., Modelska I. Expression of cyclooxygenase-2 in astrocytes of human brain after global ischemia. Folia Neuropathol. 1999, 37:75-79.
56. McAlpine F.E., Lee J.K., Harms A.S., Ruhn K.A., Blurton-Jones M., Hong J., Das P., Golde T.E., LaFerla F.M., Oddo S., Blesch A., Tansey M.G. Inhibition of soluble TNF signaling in a mouse model of Alzheimer's disease prevents pre-plaque amyloid-associated neuropathology. Neurobiol. Dis. 2009, 34:163-177.
57. McCoy M.K., Tansey M.G. TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease. J. Neuroinflammation 2008, 5:45.
58. McGeer E.G., McGeer P.L. Inflammatory processes in Alzheimer's disease. Prog. Neuropsychopharmacol. Biol. Psychiatry 2003, 27:741-749.
59. McKee A.C., Carreras I., Hossain L., Ryu H., Klein W.L., Oddo S., LaFerla F.M., Jenkins B.G., Kowall N.W., Dedeoglu A. Ibuprofen reduces Abeta, hyperphosphorylated tau and memory deficits in Alzheimer mice. Brain Res. 2008, 1207:225-236.
60. Medeiros R., Prediger R.D., Passos G.F., Pandolfo P., Duarte F.S., Franco J.L., Dafre A.L., Di Giunta G., Figueiredo C.P., Takahashi R.N., Campos M.M., Calixto J.B. Connecting TNF-alpha signaling pathways to iNOS expression in a mouse model of Alzheimer's disease: relevance for the behavioral and synaptic deficits induced by amyloid beta protein. J. Neurosci. 2007, 27:5394-5404.
61. Medeiros R., Figueiredo C.P., Pandolfo P., Duarte F.S., Prediger R.D., Passos G.F., Calixto J.B. The role of TNF-alpha signaling pathway on COX-2 upregulation and cognitive decline induced by beta-amyloid peptide. Behav. Brain Res. 2010, 209:165-173.
62. Minghetti L. Role of COX-2 in inflammatory and degenerative brain diseases. Subcell. Biochem. 2007, 42:127-141.
63. Mitchell J.A., Akarasereenont P., Thiemermann C., Flower R.J., Vane J.R. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc. Natl. Acad. Sci. U. S. A. 1993, 90:11693-11697.
64. Nakahira K., Haspel J.A., Rathinam V.A., Lee S.J., Dolinay T., Lam H.C., Englert J.A., Rabinovitch M., Cernadas M., Kim H.P., Fitzgerald K.A., Ryter S.W., Choi A.M. Autophagy proteins regulate innate immune responses by inhibiting the release of mitochondrial DNA mediated by the NALP3 inflammasome. Nat. Immunol. 2011, 12:222-230.
65. Olleros M.L., Guler R., Vesin D., Parapanov R., Marchal G., Martinez-Soria E., Corazza N., Pache J.C., Mueller C., Garcia I. Contribution of transmembrane tumor necrosis factor to host defense against Mycobacterium bovis bacillus Calmette-guerin and Mycobacterium tuberculosis infections. Am. J. Pathol. 2005, 166:1109-1120.
66. O'Neill L.A. The interleukin-1 receptor/Toll-like receptor superfamily: 10 years of progress. Immunol. Rev. 2008, 226:10-18.
67. O'Neill L.A., Kaltschmidt C. NF-kappa B: a crucial transcription factor for glial and neuronal cell function. Trends Neurosci. 1997, 20:252-258.
68. Pasinetti G.M., Aisen P.S. Cyclooxygenase-2 expression is increased in frontal cortex of Alzheimer's disease brain. Neuroscience 1998, 87:319-324.
69. Pasparakis M., Alexopoulou L., Episkopou V., Kollias G. Immune and inflammatory responses in TNF alpha-deficient mice: a critical requirement for TNF alpha in the formation of primary B cell follicles, follicular dendritic cell networks and germinal centers, and in the maturation of the humoral immune response. J. Exp. Med. 1996, 184:1397-1411.
70. Perea G., Navarrete M., Araque A. Tripartite synapses: astrocytes process and control synaptic information. Trends Neurosci. 2009, 32:421-431.
71. Perry R.T., Collins J.S., Wiener H., Acton R., Go R.C. The role of TNF and its receptors in Alzheimer's disease. Neurobiol. Aging 2001, 22:873-883.
72. Querfurth H.W., LaFerla F.M. Alzheimer's disease. N. Engl. J. Med. 2010, 362:329-344.
73. Ramos-Casals M., Brito-Zeron P., Soto M.J., Cuadrado M.J., Khamashta M.A. Autoimmune diseases induced by TNF-targeted therapies. Best Pract. Res. Clin. Rheumatol. 2008, 22:847-861.
74. Sandhya T.L., Ong W.Y., Horrocks L.A., Farooqui A.A. A light and electron microscopic study of cytoplasmic phospholipase A2 and cyclooxygenase-2 in the hippocampus after kainate lesions. Brain Res. 1998, 788:223-231.
75. Santello M., Bezzi P., Volterra A. TNFalpha controls glutamatergic gliotransmission in the hippocampal dentate gyrus. Neuron 2011, 69:988-1001.
76. Schroder K., Tschopp J. The inflammasomes. Cell 2010, 140:821-832.
77. Sfikakis P.P. The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions. Curr. Dir. Autoimmun. 2010, 11:180-210.
78. Shaftel S.S., Kyrkanides S., Olschowka J.A., Miller J.N., Johnson R.E., O'Banion M.K. Sustained hippocampal IL-1 beta overexpression mediates chronic neuroinflammation and ameliorates Alzheimer plaque pathology. J. Clin. Invest. 2007, 117:1595-1604.
79. Sheng J.G., Zhu S.G., Jones R.A., Griffin W.S., Mrak R.E. Interleukin-1 promotes expression and phosphorylation of neurofilament and tau proteins in vivo. Exp. Neurol. 2000, 163:388-391.
80. Shi C.S., Shenderov K., Huang N.N., Kabat J., Abu-Asab M., Fitzgerald K.A., Sher A., Kehrl J.H. Activation of autophagy by inflammatory signals limits IL-1beta production by targeting ubiquitinated inflammasomes for destruction. Nat. Immunol. 2012, 13:255-263.
81. Sofroniew M.V. Molecular dissection of reactive astrogliosis and glial scar formation. Trends Neurosci. 2009, 32:638-647.
82. Sofroniew M.V., Vinters H.V. Astrocytes: biology and pathology. Acta Neuropathol. 2010, 119:7-35.
83. Stadelmann C., Kerschensteiner M., Misgeld T., Bruck W., Hohlfeld R., Lassmann H. BDNF and gp145trkB in multiple sclerosis brain lesions: neuroprotective interactions between immune and neuronal cells?. Brain 2002, 125:75-85.
84. Sung S., Yang H., Uryu K., Lee E.B., Zhao L., Shineman D., Trojanowski J.Q., Lee V.M., Pratico D. Modulation of nuclear factor-kappa B activity by indomethacin influences A beta levels but not A beta precursor protein metabolism in a model of Alzheimer's disease. Am. J. Pathol. 2004, 165:2197-2206.
85. Tachida Y., Nakagawa K., Saito T., Saido T.C., Honda T., Saito Y., Murayama S., Endo T., Sakaguchi G., Kato A., Kitazume S., Hashimoto Y. Interleukin-1 beta up-regulates TACE to enhance alpha-cleavage of APP in neurons: resulting decrease in Abeta production. J. Neurochem. 2008, 104:1387-1393.
86. Terai K., Matsuo A., McGeer P.L. Enhancement of immunoreactivity for NF-kappa B in the hippocampal formation and cerebral cortex of Alzheimer's disease. Brain Res. 1996, 735:159-168.
87. Tracey D., Klareskog L., Sasso E.H., Salfeld J.G., Tak P.P. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol. Ther. 2008, 117:244-279.
88. Wajant H., Pfizenmaier K., Scheurich P. Tumor necrosis factor signaling. Cell Death Differ. 2003, 10:45-65.
89. Wallis R.S. Infectious complications of tumor necrosis factor blockade. Curr. Opin. Infect. Dis. 2009, 22:403-409.
90. Walsh D.M., Selkoe D.J. Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron 2004, 44:181-193.
91. Wang Q., Wu J., Rowan M.J., Anwyl R. Beta-amyloid inhibition of long-term potentiation is mediated via tumor necrosis factor. Eur. J. Neurosci. 2005, 22:2827-2832.
92. Warner T.D., Mitchell J.A. Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. FASEB J. 2004, 18:790-804.
93. Weggen S., Eriksen J.L., Das P., Sagi S.A., Wang R., Pietrzik C.U., Findlay K.A., Smith T.E., Murphy M.P., Bulter T., Kang D.E., Marquez-Sterling N., Golde T.E., Koo E.H. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 2001, 414:212-216.
94. Weggen S., Eriksen J.L., Sagi S.A., Pietrzik C.U., Ozols V., Fauq A., Golde T.E., Koo E.H. Evidence that nonsteroidal anti-inflammatory drugs decrease amyloid {beta}42 production by direct modulation of {gamma}-secretase activity. J. Biol. Chem. 2003, 278:31831-31837.
95. WHO Dementia: A Public Health Priority 2012, World Health Organization.
96. Wyss-Coray T., Mucke L. Inflammation in neurodegenerative disease-a double-edged sword. Neuron 2002, 35:419-432.
97. Xie W.L., Chipman J.G., Robertson D.L., Erikson R.L., Simmons D.L. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc. Natl. Acad. Sci. U. S. A. 1991, 88:2692-2696.
98. Yang Y., Quitschke W.W., Brewer G.J. Upregulation of amyloid precursor protein gene promoter in rat primary hippocampal neurons by phorbol ester, IL-1 and retinoic acid, but not by reactive oxygen species. Brain Res. Mol. Brain Res. 1998, 60:40-49.
99. Yermakova A.V., O'Banion M.K. Downregulation of neuronal cyclooxygenase-2 expression in end stage Alzheimer's disease. Neurobiol. Aging 2001, 22:823-836.
100. Zhou Y., Su Y., Li B., Liu F., Ryder J.W., Wu X., Gonzalez-DeWhitt P.A., Gelfanova V., Hale J.E., May P.C., Paul S.M., Ni B. Nonsteroidal anti-inflammatory drugs can lower amyloidogenic Abeta42 by inhibiting Rho. Science 2003, 302:1215-1217.